---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-084629"
form_type: "8-K"
ticker: null
cik: "0001850079"
company_name: "Telesis Bio Inc."
filed_at: "2024-07-18T23:59:59+00:00"
generated_at: "2026-05-31T19:49:32.387162+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Telesis Bio enters $5.85M promissory notes at 12% from major shareholders, repays MidCap debt, expands board

## Summary
- Issued $5.85M promissory notes to Novalis and Northpond at 12% annual interest, maturing Jan 16, 2026.
- Repaid $5.84M to MidCap Financial, terminating existing term and revolver loan agreements.
- Board expanded from 8 to 13; five new directors appointed: Hlavinka, Golub, Hodges, Weissman, Krueger.
- Side letter gives lenders board control: majority of nominating committee, replacement rights while >10% ownership.
- Registration rights waiver defers liquidated damages and waives accrued interest for a set period.

## SEC filing metadata
- accession: 0000950170-24-084629
- form_type: 8-K
- cik: 0001850079
- company_name: Telesis Bio Inc.
- filed_at: 2024-07-18T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 1.02, 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1850079/000095017024084629/0000950170-24-084629-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1850079/000095017024084629/tbio-20240716.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-084629
- JSON: https://secwatch.observer/filing/0000950170-24-084629.json
- Plain text: https://secwatch.observer/filing/0000950170-24-084629.txt

## Key facts
- Executive change
  Sarah Hlavinka was appointed as Director at Telesis Bio Inc..
  - Action: appointed
  - Role: Director
  source text: appointed each of Sarah Hlavinka, Steve Golub, Michael Hodges, James Weissman, and Todd Krueger (collectively, the “New Directors”), as members of the Board to fill the five vacancies.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1850079/000095017024084629/0000950170-24-084629-index.htm
- Executive change
  James Weissman was appointed as Director at Telesis Bio Inc..
  - Action: appointed
  - Role: Director
  source text: appointed each of Sarah Hlavinka, Steve Golub, Michael Hodges, James Weissman, and Todd Krueger (collectively, the “New Directors”), as members of the Board to fill the five vacancies.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1850079/000095017024084629/0000950170-24-084629-index.htm
- Executive change
  Todd Krueger was appointed as Director at Telesis Bio Inc..
  - Action: appointed
  - Role: Director
  source text: appointed each of Sarah Hlavinka, Steve Golub, Michael Hodges, James Weissman, and Todd Krueger (collectively, the “New Directors”), as members of the Board to fill the five vacancies.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1850079/000095017024084629/0000950170-24-084629-index.htm
- Executive change
  Steve Golub was appointed as Director at Telesis Bio Inc..
  - Action: appointed
  - Role: Director
  source text: appointed each of Sarah Hlavinka, Steve Golub, Michael Hodges, James Weissman, and Todd Krueger (collectively, the “New Directors”), as members of the Board to fill the five vacancies.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1850079/000095017024084629/0000950170-24-084629-index.htm
- Executive change
  Michael Hodges was appointed as Director at Telesis Bio Inc..
  - Action: appointed
  - Role: Director
  source text: appointed each of Sarah Hlavinka, Steve Golub, Michael Hodges, James Weissman, and Todd Krueger (collectively, the “New Directors”), as members of the Board to fill the five vacancies.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1850079/000095017024084629/0000950170-24-084629-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.